Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.
8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million ; Cell Processing revenue guidance increased to $70.
0 million to $71.0 million Conference call begins at 4:30 p.m.
Eastern time today BOTHELL, Wash. , Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc.
(Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended June 30, 2024 and updated revenue guidance for 2024. "We are pleased with our second quarter results. The business has stabilized and momentum continues with our third consecutive quarter of sequential revenue growth.
With our continued focus on streamlining the business, we are now beginning to benefit from the strength of our high margin, recurring and consumable product offerings," said Roderick de Greef , Chairman and CEO. "Our focus on our core cell processing product platform is emerging in our financial performance, with notable expansions in gross margin, increased adjusted EBITDA, and encouraging momentum into the second half of the year." de Greef continued, "As a pure play enabler of CGT's g.